biostudies-literatureBozonnat ASwiss National Science Foundation102679https://www.ebi.ac.uk/biostudies/studies/S-EPMC11245986biostudies-literatureUnknown73<h4>Background</h4>Sézary syndrome is an extremely rare and fatal cutaneous T-cell lymphoma (CTCL). Mogamulizumab, an anti-CCR4 monoclonal antibody, has recently been associated with increased progression-free survival in a randomized clinical trial in CTCL. We aimed to evaluate OS and prognostic factors in Sézary syndrome, including treatment with mogamulizumab, in a real-life setting.<h4>Methods</h4>Data from patients with Sézary (ISCL/EORTC stage IV) and pre-Sézary (stage IIIB) syndrome diagnosed from 2000 to 2020 were obtained from 24 centers in Europe. Age, disease stage, plasma lactate dehydrogenases levels, blood eosinophilia at diagnosis, large-cell transformation and treatment received were analyzed in a multivariable Cox proportional hazard ratio model. This study has been registEClinicalMedicineReal-life efficacy of immunotherapy for Sezary syndrome: a multicenter observational cohort study.PMC11245986200253Faiz SPerier-Muzet MDobos GDereure ODalle Sde Masson AChasset FFeldmeyer LMontlahuc CBozonnat ARam-Wolff CAmatore FMoins-Teisserenc HQuereux GMichel CAubin FTedbirt BBoulinguez SSaiag PAdamski HMaubec EBouaziz JDResche-Rigon MGrange FBejar CTroin LSerret-Larmande AMontaudie HMourah SMortier LBattistella MBonnet NViguier MAPham-Ledard AHainaut EBeltraminelli HGuenova EBeylot-Barry MD'Incan MBens GBrunet-Possenti FTemplier IIngen-Housz-Oro SCutaneous Lymphomas French Study GroupFranck NDonzel MJoly PBagot MMachet LfalseReal-life efficacy of immunotherapy for Sezary syndrome: a multicenter observational cohort study.<h4>Background</h4>Sézary syndrome is an extremely rare and fatal cutaneous T-cell lymphoma (CTCL). Mogamulizumab, an anti-CCR4 monoclonal antibody, has recently been associated with increased progression-free survival in a randomized clinical trial in CTCL. We aimed to evaluate OS and prognostic factors in Sézary syndrome, including treatment with mogamulizumab, in a real-life setting.<h4>Methods</h4>Data from patients with Sézary (ISCL/EORTC stage IV) and pre-Sézary (stage IIIB) syndrome diagnosed from 2000 to 2020 were obtained from 24 centers in Europe. Age, disease stage, plasma lactate dehydrogenases levels, blood eosinophilia at diagnosis, large-cell transformation and treatment received were analyzed in a multivariable Cox proportional hazard ratio model. This study has been regist2024-01-01T00:00:00Z2024 Jul2026-06-03T01:09:53.674Z2025-02-19T02:34:36.369ZS-EPMC112459863900706210.1016/j.eclinm.2024.102679